- Home
- KF vs CRBU Comparison
KF vs CRBU Comparison
Compare KF & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- CRBU
- Stock Information
- Founded
- KF 1984
- CRBU 2011
- Country
- KF United States
- CRBU United States
- Employees
- KF N/A
- CRBU N/A
- Industry
- KF Investment Managers
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- KF Finance
- CRBU Health Care
- Exchange
- KF Nasdaq
- CRBU Nasdaq
- Market Cap
- KF 90.9M
- CRBU 93.0M
- IPO Year
- KF N/A
- CRBU 2021
- Fundamental
- Price
- KF $22.93
- CRBU $0.97
- Analyst Decision
- KF
- CRBU Strong Buy
- Analyst Count
- KF 0
- CRBU 4
- Target Price
- KF N/A
- CRBU $8.50
- AVG Volume (30 Days)
- KF 18.4K
- CRBU 991.2K
- Earning Date
- KF 01-01-0001
- CRBU 05-08-2025
- Dividend Yield
- KF N/A
- CRBU N/A
- EPS Growth
- KF N/A
- CRBU N/A
- EPS
- KF N/A
- CRBU N/A
- Revenue
- KF N/A
- CRBU $9,918,000.00
- Revenue This Year
- KF N/A
- CRBU N/A
- Revenue Next Year
- KF N/A
- CRBU $161.81
- P/E Ratio
- KF N/A
- CRBU N/A
- Revenue Growth
- KF N/A
- CRBU N/A
- 52 Week Low
- KF $18.30
- CRBU $0.66
- 52 Week High
- KF $25.56
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- KF 67.99
- CRBU 50.97
- Support Level
- KF $21.20
- CRBU $0.98
- Resistance Level
- KF $22.87
- CRBU $1.21
- Average True Range (ATR)
- KF 0.36
- CRBU 0.10
- MACD
- KF 0.10
- CRBU 0.01
- Stochastic Oscillator
- KF 98.86
- CRBU 46.69
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.